Dr. Mary Potasek will discuss latest involvement of Simphotek in recent and new LALC and CAO clinical studies.

Simphotek partners with Penn in developing an In Situ System for Treatment of Mesothelioma

Simphotek is happy to announce a new addition to the Scientific Advisory Board, Abraham Wu, MD, a Harvard-educated radiation oncologist...

New Jersey Tech Weekly, Sep 30, 2020 – Suppose there is a therapy in development that could treat your internal solid tumors and...

Simphotek, Inc. has been selected as one of 20 company Finalist to pitch to Onelin Capital and 400+ global early-stage investors Onelin...

Simphotek, Inc, a leading edge biotech company, developing noninvasive personalized products for treating internal solid tumors, was...

Simphotek has been selected as one of the showcase companies for the 2020-2021 NCI SBIR Investor Initiatives. As a MedTech company, it...

Scientia, 2019 – Simphotek treatment planning and computational dosimetry software Dosie™ can be pivotal in widespread adaptation of...

International Photodynamic Association World Congress, 2019 (Boston, USA) – Simphotek announces a new addition to its simulation software...

SPIE BiOS, 2019 (Optical Methods for Tumor Treatment and Detection) – We introduce our Dosie modeling software that helps in predicting...